[go: up one dir, main page]

PE20181345A1 - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer

Info

Publication number
PE20181345A1
PE20181345A1 PE2018000612A PE2018000612A PE20181345A1 PE 20181345 A1 PE20181345 A1 PE 20181345A1 PE 2018000612 A PE2018000612 A PE 2018000612A PE 2018000612 A PE2018000612 A PE 2018000612A PE 20181345 A1 PE20181345 A1 PE 20181345A1
Authority
PE
Peru
Prior art keywords
quinolin
imidazo
hydro
methyl
compounds
Prior art date
Application number
PE2018000612A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Thomas Anthony Hunt
Andrew John Eatherton
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20181345A1 publication Critical patent/PE20181345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Referido a compuestos imidazo[4,5-c]quinolin-2-ona de formula (I), donde R1 es metilo; R2 es hidro o metilo; X es 1 o 2; R3 es cicloalquilo C4-C6 opcionalmente sustituido con un grupo metoxi, isopropilo, entre otros; R4 es hidro o metilo; y R5 es hidro o fluor. Tambien se refiere a composiciones farmaceuticas que los comprenden y metodos de preparacion. Dichos compuestos modulan selectivamente la cinasa de la ataxia telangiectasia mutada (ATM), por lo que son utiles para tratar o prevenir una enfermedad mediada por ATM, incluido el cancer.
PE2018000612A 2015-11-03 2016-11-02 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer PE20181345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1519406.1A GB201519406D0 (en) 2015-11-03 2015-11-03 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
PE20181345A1 true PE20181345A1 (es) 2018-08-22

Family

ID=55130605

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000612A PE20181345A1 (es) 2015-11-03 2016-11-02 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer

Country Status (20)

Country Link
US (1) US20180318287A1 (es)
EP (1) EP3371183A1 (es)
JP (1) JP2018536649A (es)
KR (1) KR20180070703A (es)
CN (1) CN108349971A (es)
AU (1) AU2016348546B2 (es)
BR (1) BR112018007772A2 (es)
CA (1) CA3002608A1 (es)
CL (1) CL2018001146A1 (es)
CO (1) CO2018003969A2 (es)
CR (1) CR20180307A (es)
GB (1) GB201519406D0 (es)
HK (2) HK1257678A1 (es)
IL (1) IL258818A (es)
MX (1) MX2018005445A (es)
PE (1) PE20181345A1 (es)
PH (1) PH12018500958A1 (es)
RU (1) RU2018120318A (es)
SV (1) SV2018005663A (es)
WO (1) WO2017076895A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP4516318A3 (en) 2018-09-14 2025-04-30 Suzhou Zanrong Pharma Limited 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
BR112021005989A2 (pt) * 2018-09-30 2021-06-29 Medshine Discovery Inc. derivados de quinolino-pirrolidin-2-ona e aplicação dos mesmos
MA55198A (fr) * 2019-03-05 2022-01-12 Astrazeneca Ab Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN115003672A (zh) * 2020-01-09 2022-09-02 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022128833A1 (en) 2020-12-15 2022-06-23 Merck Patent Gmbh Solid transition metal-ligand complexes
MX2024009184A (es) * 2022-01-26 2024-07-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto que contiene grupo hidrazino.
CA3245563A1 (en) * 2022-04-11 2023-10-19 Wei Zhong CRYSTALLINE FORM OF DERIVED 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO [4,5-C]QUINOLIN-2-ONE, CRYSTALLINE SALT FORM, PREPARATION AND APPLICATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528829A (ja) * 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (es) * 2014-05-08 2018-04-21
PT3560924T (pt) * 2015-04-02 2021-07-02 Merck Patent Gmbh Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm

Also Published As

Publication number Publication date
JP2018536649A (ja) 2018-12-13
CO2018003969A2 (es) 2018-07-10
CA3002608A1 (en) 2017-05-11
RU2018120318A3 (es) 2019-12-24
WO2017076895A1 (en) 2017-05-11
RU2018120318A (ru) 2019-12-05
SV2018005663A (es) 2018-07-20
PH12018500958A1 (en) 2018-11-19
MX2018005445A (es) 2018-08-14
AU2016348546B2 (en) 2019-05-02
CL2018001146A1 (es) 2018-09-04
AU2016348546A1 (en) 2018-06-14
EP3371183A1 (en) 2018-09-12
US20180318287A1 (en) 2018-11-08
GB201519406D0 (en) 2015-12-16
HK1255598A1 (zh) 2019-08-23
BR112018007772A2 (pt) 2018-10-30
KR20180070703A (ko) 2018-06-26
IL258818A (en) 2018-06-28
CN108349971A (zh) 2018-07-31
CR20180307A (es) 2018-10-05
HK1257678A1 (zh) 2019-10-25

Similar Documents

Publication Publication Date Title
PE20181345A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2021009673A (es) Moduladores de ror-gamma.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
MX2018004664A (es) Antagonistas de ep4.
CL2015002835A1 (es) Nuevos derivados de piridina
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX377004B (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.